This is especially important in the search for pharmacological targets to treat metabolic diseases, since direct p53 manipulation could always lead to broad downstream effects and/or diminished tumor suppression, while therapeutically aiming at single downstream factors could evoke more focused treatment outcomes. Here, TP53 is linked to Other metabolic disease.